ClinicalTrials.gg
CompletedNCT04303156Updated Oct 28, 2021Results posted

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

A Phase 1 interventional study of Islatravir in Human Immunodeficiency Virus (HIV) Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to participants in good health.

02

Conditions studied

  • Human Immunodeficiency Virus (HIV) Infection

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 12 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy participants must have the following:

  • Is in good health
  • Has a (BMI) ≥18.5 and ≤40 kg/m2.
  • Female is not pregnant or breastfeeding, and is not one of the following: a woman of (WOCBP); if a WOCBP, is using an acceptable method, or is abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention

Renally impaired participants must have the following:

  • With the exception of renal impairment, is in generally good health
  • Has a BMI ≥ 18.5 and ≤ 40 kg/m2
  • Female is not pregnant or breastfeeding, and is not one of the following: a woman of childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention

Exclusion criteria

Exclusion Criteria:

Healthy participants must have the following:

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Is mentally or legally incapacitated, has significant emotional problems
  • Has known to the active substance or any of the of the study drug
  • Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Is positive for surface antigen, antibodies or .
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within prior 4 weeks
  • Is taking medications to treat chronic medical conditions and/or conditions associated with renal disease
  • Has participated in another study within prior 4 weeks

Other exclusions for healthy participants:

  • Does not agree to follow the smoking restrictions
  • Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages per day
  • Consumes excessive amounts,of caffeinated beverages per day.
  • Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately prior 3 months.

Renally impaired participants must have the following:

  • Has a history or presence of renal artery stenosis.
  • Has had a renal transplant or nephrectomy.
  • Has rapidly fluctuating renal function as determined by historical measurements.
  • Has known hypersensitivity to the active substance or any of the excipients of the study drug.
  • Has a history of cancer ().
  • Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV).
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
  • Is taking medications to treat chronic medical conditions and/or conditions associated with renal disease and has not been on a stable regimen for at least 1 month and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours after administration of the study drug.
  • Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit.

Other exclusions for renally impaired participants

  • Does not agree to follow the smoking restrictions.
  • Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages per day.
  • Consumes excessive amounts of caffeinated beverages per day.
  • Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 months.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Severe Renal Impairment

    Participants with severe renal impairment received a single oral dose of 60 mg MK-8591 (Islatravir) administered in capsule form.

    Drug: Islatravir

  • Experimental
    Healthy

    Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.

    Drug: Islatravir

Interventions

  • Single oral dose of 60 mg Islatravir administered in capsule form

    Also known as: MK-8591

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)

    Participants were treated with islatravir (ISL), and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose

  2. Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose

  3. Maximum Concentration (Cmax) of Plasma ISL

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose

  4. Time of Maximum Concentration (Tmax) of Plasma ISL

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Tmax of plasma ISL was expressed as a median.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose

  5. Apparent Terminal Half-life (t1/2) of Plasma ISL

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose

  6. Apparent Clearance (CL/F) of Plasma ISL

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose

  7. Apparent Volume of Distribution (Vz/F) of Plasma ISL

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose

Secondary outcomes

  1. AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)

    Participants were treated with ISL, and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 4, 24, 48, 96, 168 hours post-dose

  2. AUC0-last of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 4, 24, 48, 96, 168 hours post-dose

  3. Cmax of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 4, 24, 48, 96, 168 hours post-dose

  4. Tmax of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Tmax of ISL-TP was expressed as a median.

    Time frame: Pre-dose, 4, 24, 48, 96, 168 hours post-dose

  5. Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected at 24 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: 24 hours post-dose

  6. Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected at 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: 168 hours post-dose

  7. Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected at 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: 672 hours post-dose

  8. T1/2 of ISL-TP in PBMC

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The t1/2 of plasma ISL was expressed as a geometric mean. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

    Time frame: Pre-dose, 4, 24, 48, 96, 168 hours post-dose

  9. Percentage of Participants With an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to Day 29

  10. Percentage of Participants Who Discontinued From the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to Day 29

07

Results

Posted Oct 28, 2021

Participant flow

Male and females with severe renal impairment between the ages of 18 and 75 years old (inclusive), and healthy matched controls were enrolled in this study.

Participant flow — Overall Study
MilestoneSevere Renal ImpairmentHealthy
Started66
Completed66
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)

Participants were treated with islatravir (ISL), and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose
Reported as:
Geometric mean · hr*μM
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)
hr*μMSevere Renal ImpairmentHealthy
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)14.4 (11.8 to 17.6)6.54 (4.77 to 8.98)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 2.20 · 90% CI 1.68 to 2.88Severe Renal Impairment / Healthy
PrimaryArea Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose
Reported as:
Geometric mean · hr*μM
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL
hr*μMSevere Renal ImpairmentHealthy
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL11.0 (9.17 to 13.1)5.68 (4.06 to 7.94)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 1.93 · 90% CI 1.46 to 2.55Severe Renal Impairment / Healthy
PrimaryMaximum Concentration (Cmax) of Plasma ISL

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose
Reported as:
Geometric mean · μM
Maximum Concentration (Cmax) of Plasma ISL
μMSevere Renal ImpairmentHealthy
Maximum Concentration (Cmax) of Plasma ISL1.23 (1.06 to 1.42)1.19 (0.699 to 2.04)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 1.03 · 90% CI 0.67 to 1.57Severe Renal Impairment / Healthy
PrimaryTime of Maximum Concentration (Tmax) of Plasma ISL

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Tmax of plasma ISL was expressed as a median.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose
Reported as:
Median · Hours
Time of Maximum Concentration (Tmax) of Plasma ISL
HoursSevere Renal ImpairmentHealthy
Time of Maximum Concentration (Tmax) of Plasma ISL1.03 (1.00 to 2.00)0.75 (0.5 to 1.00)
PrimaryApparent Terminal Half-life (t1/2) of Plasma ISL

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose
Reported as:
Geometric mean · Hours
Apparent Terminal Half-life (t1/2) of Plasma ISL
HoursSevere Renal ImpairmentHealthy
Apparent Terminal Half-life (t1/2) of Plasma ISL127 ± 7.772.0 ± 15.5
PrimaryApparent Clearance (CL/F) of Plasma ISL

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) of Plasma ISL
L/hrSevere Renal ImpairmentHealthy
Apparent Clearance (CL/F) of Plasma ISL14.2 (11.6 to 17.4)31.3 (22.8 to 42.9)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 0.46 · 90% CI 0.35 to 0.60Severe Renal Impairment / Healthy
PrimaryApparent Volume of Distribution (Vz/F) of Plasma ISL

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of Plasma ISL
LitersSevere Renal ImpairmentHealthy
Apparent Volume of Distribution (Vz/F) of Plasma ISL2610 (2170 to 3140)3250 (2100 to 5030)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 0.80 · 90% CI 0.56 to 1.14Severe Renal Impairment / Healthy
SecondaryAUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)

Participants were treated with ISL, and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 4, 24, 48, 96, 168 hours post-dose
Reported as:
Geometric mean · hr*pmol/10^6 cells
AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)
hr*pmol/10^6 cellsSevere Renal ImpairmentHealthy
AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)5810 (3890 to 8700)3920 (2830 to 5420)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 1.48 · 90% CI 1.03 to 2.14Severe Renal Impairment / Healthy
SecondaryAUC0-last of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 4, 24, 48, 96, 168 hours post-dose
Reported as:
Geometric mean · hr*pmol/10^6 cells
AUC0-last of ISL-TP in PBMC
hr*pmol/10^6 cellsSevere Renal ImpairmentHealthy
AUC0-last of ISL-TP in PBMC5200 (3670 to 7370)3780 (2720 to 5230)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 1.38 · 90% CI 0.98 to 1.93Severe Renal Impairment / Healthy
SecondaryCmax of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 4, 24, 48, 96, 168 hours post-dose
Reported as:
Geometric mean · pmol/10^6 cells
Cmax of ISL-TP in PBMC
pmol/10^6 cellsSevere Renal ImpairmentHealthy
Cmax of ISL-TP in PBMC20.3 (15.1 to 27.4)21.6 (13.7 to 34.1)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 0.94 · 90% CI 0.64 to 1.39Severe Renal Impairment / Healthy
SecondaryTmax of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Tmax of ISL-TP was expressed as a median.

Time frame:
Pre-dose, 4, 24, 48, 96, 168 hours post-dose
Reported as:
Median · Hours
Tmax of ISL-TP in PBMC
HoursSevere Renal ImpairmentHealthy
Tmax of ISL-TP in PBMC36.00 (24.00 to 240.12)24.00 (4.00 to 239.78)
SecondaryConcentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected at 24 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
24 hours post-dose
Reported as:
Geometric mean · pmol/10^6 cells
Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC
pmol/10^6 cellsSevere Renal ImpairmentHealthy
Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC18.4 (14.2 to 23.8)19.0 (12.9 to 28.2)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 0.97 · 90% CI 0.69 to 1.35Severe Renal Impairment / Healthy
SecondaryConcentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected at 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
168 hours post-dose
Reported as:
Geometric mean · pmol/10^6 cells
Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC
pmol/10^6 cellsSevere Renal ImpairmentHealthy
Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC8.06 (4.69 to 13.9)4.43 (0.938 to 20.9)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 1.82 · 90% CI 0.55 to 6.02Severe Renal Impairment / Healthy
SecondaryConcentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected at 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
672 hours post-dose
Reported as:
Geometric mean · pmol/10^6 cells
Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC
pmol/10^6 cellsSevere Renal ImpairmentHealthy
Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC1.96 (0.982 to 3.92)0.730 (0.489 to 1.09)
Statistical analysis
  • Severe Renal Impairment vs Healthy · Gmr: 2.69 · 90% CI 1.51 to 4.80Severe Renal Impairment / Healthy
SecondaryT1/2 of ISL-TP in PBMC

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The t1/2 of plasma ISL was expressed as a geometric mean. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

Time frame:
Pre-dose, 4, 24, 48, 96, 168 hours post-dose
Reported as:
Geometric mean · Hours
T1/2 of ISL-TP in PBMC
HoursSevere Renal ImpairmentHealthy
T1/2 of ISL-TP in PBMC181 ± 48.4131 ± 19.0
SecondaryPercentage of Participants With an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event (AE)
Percentage of participantsSevere Renal ImpairmentHealthy
Percentage of Participants With an Adverse Event (AE)16.70.0
SecondaryPercentage of Participants Who Discontinued From the Study Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued From the Study Due to an AE
Percentage of participantsSevere Renal ImpairmentHealthy
Percentage of Participants Who Discontinued From the Study Due to an AE0.00.0

Adverse events

Collected over Adverse Events (AEs) from day of treatment (Day 1) up to day 29. All-cause mortality from day of randomization (Day 1) up to day 29.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severe Renal Impairment0/6 (0%)0/6 (0%)1/6 (16.7%)
Healthy0/6 (0%)0/6 (0%)0/6 (0%)
Most frequent other events
Most frequent other events
EventSevere Renal ImpairmentHealthy
Pain in extremityMusculoskeletal and connective tissue disorders1/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Severe Renal ImpairmentHealthyTotal
Mean57.7 ± 12.958.8 ± 5.558.3 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Severe Renal ImpairmentHealthyTotal
Female123
Male549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Severe Renal ImpairmentHealthyTotal
Hispanic or Latino336
Not Hispanic or Latino336
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Severe Renal ImpairmentHealthyTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White6511
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Clinical Pharmacology of Miami ( Site 0001)
    Miami, Florida 33014, United States
  • Charite Research Organisation GmbH ( Site 0003)
    Berlin, 10117, Germany
09

References and documents

Publications

  • Matthews RP, Cao Y, Patel M, Weissler VL, Bhattacharyya A, De Lepeleire I, Last S, Rondon JC, Vargo R, Stoch SA, Iwamoto M. Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093122. doi: 10.1128/aac.00931-22. Epub 2022 Nov 8. PubMed 36346229 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Oct 2020, 4 months.

Results were first posted in Oct 2021, 1 year after primary completion.

Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 4 months is below that.

Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2020
First posted
Mar 10, 2020
StartActual
Jun 18, 2020
Primary completionActual
Oct 19, 2020
CompletionActual
Oct 19, 2020
Results first posted
Oct 28, 2021
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04303156
Responsible party
Sponsor
First posted
Mar 10, 2020
Start date
Jun 18, 2020
Primary completion
Oct 19, 2020
Completion
Oct 19, 2020
Results posted
Oct 28, 2021
Last update
Oct 28, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Islatravir

Start the discussion